Story

Veraxa Biotech Shares Rise on Appointment of New CFO Raju Willener

ENTHMSVIIDZHZH-TWJAKOHI
Sep 4, 20261 min read
Veraxa Biotech Shares Rise on Appointment of New CFO Raju Willener
Text size
Background

Shares of Veraxa Biotech AG (NASDAQ:VRXA) gained 4.6% on Friday after the company named veteran finance executive Raju Willener as its new Chief Financial Officer, effective immediately. The appointment comes as the biotechnology firm advances its pipeline of cancer therapies.

Executive Transition Details

Veraxa Biotech confirmed in a statement that Willener will take over the CFO role from Carl von Halem. He will report directly to CEO and Co-Founder Christoph Antz. The company noted the leadership change is occurring as it focuses on developing its BiTAC technology platform and oncology pipeline.

A Veteran Financial Leader

Willener brings more than three decades of experience in corporate finance and global capital markets to Veraxa. His career includes senior executive positions where he oversaw investment portfolios exceeding CHF 30 billion in assets under management across the U.S., Europe, and Asia.

Sample IUX Markets – In-articleAd

Prior to joining Veraxa, Willener's most recent role was CFO at Exentis Group AG, a position he was appointed to in 2025 after serving as Director of Corporate Development. In that capacity, he was responsible for leading M&A initiatives and financial strategy. He holds an MBA and a Master’s degree in Accounting and Finance.

Context for Investors

The positive market reaction underscores investor confidence in the appointment of a seasoned financial leader as Veraxa enters a critical phase of development. The company specializes in creating antibody-based cancer treatments, and strong financial stewardship is crucial for funding research, development, and potential commercialization of its BiTAC platform.

Read next

More on Stocks
Back to latest news

LATEST